Capricor expands board to 8, appoints former Novartis BD executive Philip Gotwals

CAPRICOR THERAPEUTICS, INC.

Board increased from 7 to 8 directors; Philip Gotwals, Ph.D. elected effective July 21, 2023.
Gotwals brings nearly 30 years biotech experience, most recently Global Head of BD at Novartis.
Received initial grant of nonstatutory stock option to purchase 115,000 shares, vesting over 4 years.
Will not initially serve on any committee; standard indemnification agreement.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Philip Gotwals

Director

CAPR · CAPRICOR THERAPEUTICS, INC.

Effective: 2023-07-21
Filed: July 24, 2023, 7:59 PM ET

approved an increase of the size of the Board from seven to eight directors, and elected Philip Gotwals, Ph.D. as a member of the Board to fill the newly created vacancy, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Philip Gotwals was elected as Director at CAPRICOR THERAPEUTICS, INC..

Action: elected
Role: Director

Exact text from the filing

approved an increase of the size of the Board from seven to eight directors, and elected Philip Gotwals, Ph.D. as a member of the Board to fill the newly created vacancy, effective immediately.

View on SEC.gov

CAPRICOR THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001558370-23-012106

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.